TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10549460

Group type: EXPERIMENTAL
Intervention: Propofol infusion, 1 mg kg‐1 min‐1 intravenous for 2 min, followed by propofol infusion, 200 micrograms kg‐1 min‐1
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, 1 microgram kg‐1 intravenous + propofol infusion as in Group P
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, 2 micrograms kg‐1 intravenous + propofol infusion as in Group P
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, 3 micrograms kg‐1 intravenous + propofol infusion as in Group P
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bispectral index values in nonmovement vs. movement category
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bispectral index and 95% spectral edge frequency monitoring
Number of subjects: 68
Study: 7597608

Group type: EXPERIMENTAL
Intervention: Golytely with sodium sulfate (47 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Golytely without sodium sulfate (49 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Golytely with sodium sulfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Golytely without sodium sulfate
Number of subjects: 100
Study: 2193629

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 153862

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide treatment for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide treatment for 1 week
Number of subjects: 0
Study: 30987164

Group type: EXPERIMENTAL
Intervention: Hydromorphone treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Plasma miRNA signature
Number of subjects: 25
Study: 28692170

Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS after late first-trimester MTOP
Number of subjects: 159

Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS after late first-trimester MTOP
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS after second-trimester MTOP
Number of subjects: 159

Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS after second-trimester MTOP
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Immediate and delayed insertion of LNG-IUS
Number of subjects: 159
Study: 25708147

Group type: EXPERIMENTAL
Intervention: Rituximab (1 gm at weeks 0 and 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23072513

Group type: EXPERIMENTAL
Intervention: Tailored cessation advice report and progress report
Number of subjects: 6697

Group type: COMPARATOR
Intervention: Standard non-tailored information
Number of subjects: 6697
Study: 21403073

Group type: EXPERIMENTAL
Intervention: Early percutaneous tracheotomy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Prolonged intubation
Number of subjects: 216
Study: 19538233

Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-GI meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-GI meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-calorie meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 10
Study: 17305271

Group type: EXPERIMENTAL
Intervention: Asymmetric hearing loss (more than 10 dB difference between ears)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Binaural difference in hearing threshold level
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Age, handedness, and sex
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Left ear's hearing threshold level
Number of subjects: 429
Study: 15370684

Group type: EXPERIMENTAL
Intervention: 4% ethanol solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10% ethanol solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% ethanol solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose 5.5% (w/v)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose 11.4% (w/v)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (500 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (250 mL)
Number of subjects: 10
Study: 11867933

Group type: EXPERIMENTAL
Intervention: Etidronate (EHDP) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Parathyroidectomy (PTX)
Number of subjects: 22
Study: 10221416

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily (q.i.d.)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily (b.i.d.)
Number of subjects: 215
Study: 8657840

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg PO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: scopolamine (0.5 mg IV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: glycopyrrolate (0.2 mg IV)
Number of subjects: 36
Study: 2110943

Group type: EXPERIMENTAL
Intervention: 1 g L-ascorbic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6772045

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition preoperatively (group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition postoperatively (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fasting until 3 h after surgical intervention (group 3)
Number of subjects: 3
Study: 31538372

Group type: EXPERIMENTAL
Intervention: Osmotic‐Release Oral System Methylphenidate (OROS‐MPH)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 30387461

Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Water-based gel (Control)
Number of subjects: 60
Study: 26955179

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 50
Study: 24460827

Group type: EXPERIMENTAL
Intervention: DOTS with SMS reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: DOTS (control group, no SMS intervention)
Number of subjects: 0
Study: 21987042

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ondansetron alone (Control)
Number of subjects: 150
Study: 20429978

Group type: EXPERIMENTAL
Intervention: SARMA software
Number of subjects: 29

Group type: COMPARATOR
Intervention: Other methods (letter and direct invitation by a practice nurse)
Number of subjects: 29
Study: 17187983

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 173
Study: 14706049

Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor blockers (ARBs)
Number of subjects: 3
Study: 12324291

Group type: EXPERIMENTAL
Intervention: L-796568 (375 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9750733

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 26
Study: 8151001

Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate sustained release tablets, dosages titrated from 30 mg/day up to a maximum of 120 mg/day.
Number of subjects: 0
Study: 3072354

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus codeine 60 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 29576114

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) using oesophageal Doppler monitor, aimed to maintain stroke volume, mean arterial pressure >70 mm Hg, and cardiac index ≥2.5 litres min‐1 m‐2
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group with intraoperative fluids based on traditional principles
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT)
Number of subjects: 450
Study: 28526466

Group type: EXPERIMENTAL
Intervention: Standard group (n=60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rotational group (n=60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Triple group (n=60)
Number of subjects: 180
Study: 25588353

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) in LCIG-naïve patients (N = 29)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) in continuing-LCIG patients (N = 33)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clinical Global Impression-Improvement scale rating for both groups
Number of subjects: 62
Study: 23660512

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (ILS)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 724
Study: 20185731

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subcutaneous insulin (CSII)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CIPII
Number of subjects: 24

Group type: COMPARATOR
Intervention: CSII
Number of subjects: 24
Study: 18232724

Group type: EXPERIMENTAL
Intervention: Levetiracetam (maximum dose of 3000 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16801586

Group type: EXPERIMENTAL
Intervention: Community-based intervention to increase physical activity over 3 years.
Number of subjects: 2950
Study: 12756090

Group type: EXPERIMENTAL
Intervention: TURP plus HIFU
Number of subjects: 271

Group type: COMPARATOR
Intervention: HIFU
Number of subjects: 271
Study: 10762579

Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir (10 mg twice daily for 5 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8985910

Group type: EXPERIMENTAL
Intervention: 200-ms gap during fixation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 200-ms gap during pursuit
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intermediate gap durations during fixation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intermediate gap durations during pursuit
Number of subjects: 4

Group type: COMPARATOR
Intervention: No gap
Number of subjects: 4
Study: 8103820

Group type: EXPERIMENTAL
Intervention: Monoclonal-antibody-purified FVIII concentrates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermediate-purity FVIII concentrates
Number of subjects: 60
Study: 3529800

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both tranexamic acid and naproxen
Number of subjects: 30
Study: 30290903

Group type: EXPERIMENTAL
Intervention: COPP/ABVD
Number of subjects: 2952

Group type: EXPERIMENTAL
Intervention: bBEACOPP
Number of subjects: 2952

Group type: EXPERIMENTAL
Intervention: eBEACOPP
Number of subjects: 2952

Group type: EXPERIMENTAL
Intervention: 4+4
Number of subjects: 2952

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 2952
Study: 27412789

Group type: EXPERIMENTAL
Intervention: D2-receptor antagonist haloperidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 20
Study: 25941810

Group type: EXPERIMENTAL
Intervention: 2 calcium-fortified cereal bars daily (total of 400 mg calcium/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 2 calcium-fortified cereal bars daily
Number of subjects: 35
Study: 24697033

Group type: EXPERIMENTAL
Intervention: JJ stent left in situ (Group I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No stent (Group II)
Number of subjects: 54
Study: 21685206

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (HBR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Day hospital rehabilitation (DHR)
Number of subjects: 89
Study: 17559359

Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, metronidazole, and amoxicillin (LBMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, tetracycline, and amoxicillin (LBTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, metronidazole, and tetracycline (LBMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17128840

Group type: EXPERIMENTAL
Intervention: 5% dexpanthenol and zinc oxide ointment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ointment base
Number of subjects: 46
Study: 14618470

Group type: EXPERIMENTAL
Intervention: 20-mg oestradiol implants, replaced every 4 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 11069229

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) daily for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 3 times weekly (TIW) for 18 months (group B)
Number of subjects: 95
Study: 9197048

Group type: EXPERIMENTAL
Intervention: Health-teaching materials at the hardest readability level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-teaching materials at the easiest readability level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-teaching materials at various readability levels
Number of subjects: 0
Study: 1439406

Group type: EXPERIMENTAL
Intervention: Test compound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3969937

Group type: EXPERIMENTAL
Intervention: Zinc intake of 18.5 mg/day for two consecutive weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zinc intake of 3.5 mg/day above the RDA for men
Number of subjects: 9
Study: 31450870

Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 137

Group type: COMPARATOR
Intervention: No endometrial scratching (control)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Endometrial scratching with long agonist protocol
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Endometrial scratching with antagonist protocol
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Previously failed IVF
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Stimulation with long agonist protocol
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Stimulation with antagonist protocol
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Number of embryos
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Number of blastocysts
Number of subjects: 137
Study: 29384859

Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Simple cleaning regimen
Number of subjects: 64
Study: 26519996

Group type: EXPERIMENTAL
Intervention: Higher beta-blocker dose
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Lower heart rate
Number of subjects: 2331
Study: 25317898

Group type: EXPERIMENTAL
Intervention: Active patients
Number of subjects: 47286

Group type: COMPARATOR
Intervention: Inactive patients
Number of subjects: 47286

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 47286

Group type: EXPERIMENTAL
Intervention: Physical activity before rehabilitation
Number of subjects: 47286

Group type: EXPERIMENTAL
Intervention: Comorbidities and age
Number of subjects: 47286
Study: 22505395

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 20569035

Group type: EXPERIMENTAL
Intervention: Bilateral sustained hamstring stretching + 60 seconds of sciatic nerve slider technique for each leg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bilateral sustained hamstring stretching
Number of subjects: 8
Study: 18070842

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15683472

Group type: EXPERIMENTAL
Intervention: 3D-guided ablation (group 1, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional fluoroscopy guidance ablation (group 2, n = 30)
Number of subjects: 60
Study: 12428179

Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine and fiber (group I)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II)
Number of subjects: 47
Study: 10325501

Group type: EXPERIMENTAL
Intervention: 4-HPR (two 100-mg capsules daily for 3 weeks)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (two capsules daily for 3 weeks)
Number of subjects: 37
Study: 8519723

Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine infusion (i.v.P) at 35 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine infusion (i.v.P) at higher doses (50 mg or 75 mg)
Number of subjects: 37
Study: 1422748

Group type: EXPERIMENTAL
Intervention: Colour duplex ultrasonography
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pulse-generated run-off (PGR)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-invasive assessment (duplex examination)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PGR
Number of subjects: 65
Study: 6320943

Group type: EXPERIMENTAL
Intervention: Low-dose corticotrophin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (corticotrophin and placebo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biplanar radiography
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neck movements
Number of subjects: 21
Study: 31190757

Group type: EXPERIMENTAL
Intervention: Proactive Interdisciplinary Self-Management (PRISMA) program, 6-month duration, two group meetings about T2DM guided by care providers.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (control group), visits at the general practice.
Number of subjects: 108
Study: 30217693

Group type: EXPERIMENTAL
Intervention: LBP+Hip group
Number of subjects: 76

Group type: COMPARATOR
Intervention: LBP only group
Number of subjects: 76
Study: 27295444

Group type: EXPERIMENTAL
Intervention: HDCIS low rate (750 pps/ch)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HDCIS high rate (1376 pps/ch)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FS4 low rate (750 pps/ch)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FS4 high rate (1376 pps/ch)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FS4 high rate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HDCIS high rate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FS4 low rate
Number of subjects: 26
Study: 24138089

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness training
Number of subjects: 103

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 103
Study: 22526531

Group type: EXPERIMENTAL
Intervention: Varenicline (4 weeks pre-quit)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (3 weeks)
Number of subjects: 57
Study: 20522594

Group type: EXPERIMENTAL
Intervention: TUDCA (1,750 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18622965

Group type: EXPERIMENTAL
Intervention: Intraoperative duplex ultrasonography (IODS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (normal or corrected relevant findings)
Number of subjects: 70
Study: 15642073

Group type: EXPERIMENTAL
Intervention: Metformin XR 1000 mg once daily
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Metformin XR 500 mg once daily
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Metformin XR 1500 mg once daily
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Metformin XR 2000 mg once daily
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Metformin XR 1000 mg twice daily
Number of subjects: 982

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Metformin XR
Number of subjects: 982
Study: 12103287

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (50 Gy in 25 fractions)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Postoperative radiotherapy (66 Gy in 33 fractions)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 190
Study: 10082501

Group type: EXPERIMENTAL
Intervention: Instant coffee (5 cups per day, equivalent to 300 mg caffeine per day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Caffeine-free diet (abstaining from caffeine-containing drinks)
Number of subjects: 48
Study: 7579751

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 6
Study: 2202240

Group type: COMPARATOR
Intervention: Antacid (Mylanta II)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: GI cocktail (antacid + 15 mL of 2% viscous lidocaine)
Number of subjects: 73
Study: 7156248

Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: L-tryptophan-amitriptyline combination
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 30921384

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standardized Episodic Thinking (SET)
Number of subjects: 53
Study: 29514254

Group type: EXPERIMENTAL
Intervention: Late pregnancy
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Postpartum period
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Nonpregnant period
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Early pregnancy
Number of subjects: 2751